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Background: Context: The clinical utility and age dependant effects of the strongest single cardiovascular disease (CVD) susceptibility gene variant 
identified thus far (on chromosome 9p21) has not yet been evaluated in any large homogeneous prospective cohort study. 
Objectives: We tested in a large prospective cohort study what proportion of CVD incidence is explained by chromosome 9p21 and whether it 
adds incremental information regarding CVD prediction on top of traditional risk factors. We also tested whether these two clinical implications were 
affected by age.
Methods: We examined 24918 subjects from the Malmö Diet and Cancer Study free from prior CVD between 1991-1996 and used multivariate 
adjusted Cox proportional hazard models to relate chromosome 9p21 (rs4977574, G-allele coded) to first incident CVD event (n=2500) during 
11.7±2.94 years of follow up. The population was divided into quartiles of baseline age and linear trends of rs4977574 effects sizes across age 
groups were estimated in logistic regression models.
Results: In additive models chromosome 9p21 significantly predicted CVD (Hazard Ratio; 95% confidence intervals) in the entire population 
(1.15, 1.09-1.22; P<0.001). Effect estimates increased from the highest (Q4) to lowest quartile (Q1) of baseline age, but this trend was not 
significant. The over-all population attributable risk conferred by chromosome 9p21 in fully adjusted models was 12%, ranging from 19% in Q1 to 
10% in Q4. Addition of chromosome 9p21 to traditional risk factors only marginally improved the C-statistic, Net Reclassification Index and Index of 
Discrimination Improvement.
Conclusions: The high population attributable risk conferred by chromosome 9p21 suggests that preventive treatment interfering with downstream 
mechanisms of the gene variation may prevent a substantial proportion of CVD incidence over a broad range of ages. On the other hand, the 
chromosome 9p21 gene variation alone does not add any clinically meaningful information in terms of CVD prediction when added to traditional risk 
factors at any age.
